Juniper Networks® Partners with Shaare Zedek Medical Center to Accelerate Digital Transformation with Automated Data Center
Juniper Networks, (NYSE: JNPR), a leader in secure, AI-driven networks, today announced that Shaare Zedek Medical Center, Jerusalem’s largest and fastest growing multi-disciplinary medical center, has embarked on total digital transformation of operations to provide superior experiences and exceptional care to its patients using Juniper’s data center solutions.
Shaare Zedek is a leading research and teaching hospital, running 30 departments and 70 outpatient clinics, which provide innovative treatments and therapies to one million patients per year. The hospital is also a model for large-scale emergency medicine and a leader in applying AI to patient care. Using Juniper® technology, the hospital built state-of-the-art data centers on its two campuses to ensure the availability of life-critical systems and applications for uninterrupted patient care and robust data analysis to guide the best courses of treatment.
News Highlights:
- Shaare Zedek uses the Juniper Apstra software to automate data center network operations, which leads to improved patient experiences. Apstra assures the network is running as intended and alerts the IT team if brownouts or deviations occur. The IT team also uses Apstra to manage changes, maintenance and updates.
- With Juniper Apstra software, Shaare Zedek has been able to deploy its network fabric faster, guarantee data center uptime with network visibility and automation, streamline network operations, resolve issues more quickly and reduce total cost of ownership for its data center network.
- The hospital operates 24x7 and cannot shut down the data center for maintenance to switches, clusters, etc. With Juniper Apstra, Shaare Zedek can fully automate changes in real time and assure continuous operations.
- The Juniper Networks® QFX5120 Switches form the data center network fabric, delivering 100-Gbps of capacity to support clinical and administrative applications and massive data stores.
- Shaare Zedek worked with Oasis Technologies, a Juniper Elite Plus partner, to create the optimal data center architecture, working on the design, validation and testing to ensure that the Juniper solutions met Shaare Zedek’s strategic operational and technical goals.
Supporting Quotes:
“Digital health is transforming patient care at Shaare Zedek. Our data center operations must ensure the continuous availability of our life-critical systems and applications. Juniper provides the foundation of our reliable data center with next-level automation that assures best practice and consistency, to intent from initial design to everyday operations.”
- Shimi Ben Baruch, Vice President & Chief Technology Officer, Shaare Zedek Medical Center
“The network plays a vital role in keeping a modern organization healthy. It allows organizations to scale and support new applications and technologies that can assist in driving better patient outcomes and experiences. Juniper Apstra provides high performance technologies for Shaare Zedek Medical Center to ensure that it is fully prepared for continued digital acceleration.”
- Gos Hein van de Wouw, Vice President, Enterprise, EMEA, Juniper Networks
Additional Resources:
- Shaare Zedek Medical Center: Success Story
- Follow Juniper Networks online: Facebook | Twitter | LinkedIn
- Juniper Blogs and Community: J-Net
About Juniper Networks
Juniper Networks is dedicated to dramatically simplifying network operations and driving superior experiences for end users. Our solutions deliver industry-leading insight, automation, security and AI to drive real business results. We believe that powering connections will bring us closer together while empowering us all to solve the world’s greatest challenges of well-being, sustainability and equality. Additional information can be found at Juniper Networks (www.juniper.net) or connect with Juniper on Twitter, LinkedIn and Facebook.
Juniper Networks, the Juniper Networks logo, Juniper, Junos, and other trademarks listed here are registered trademarks of Juniper Networks, Inc. and/or its affiliates in the United States and other countries. Other names may be trademarks of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230307005125/en/
Contact information
Media Relations:
Pelin Murphy
Juniper Networks
+44 (0) 1372 385 686
pelin@juniper.net
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Wolters Kluwer Ranks First in Dresner 2025 Wisdom of Crowds® Financial Consolidation, Close Management and Financial Reporting Market Study23.10.2025 16:30:00 EEST | Press release
Wolters Kluwer, a global leader in professional information, software solutions and services, today announced that its CCH® Tagetik Intelligent Platform has achieved the top position in the Dresner Advisory Services 2025 Wisdom of Crowds® Financial Consolidation, Close Management and Financial Reporting (FCCR) Market Study. This marks the second straight year that Wolters Kluwer has earned the study’s number one ranking. Access the Dresner Advisory Services 2025 Wisdom of Crowds® Financial Consolidation, Close Management and Financial Reporting (FCCR) Market Study. This study is part of Dresner Advisory Services’ ongoing research into the enterprise performance management (EPM) space and focuses specifically on performance management capabilities targeted at the finance function, including financial consolidation, close management and financial reporting. The study also identifies user trends, priorities, adoption patterns, and vendor performance, helping organizations make informed de
Andersen Consulting Collaborates with Acronotics to Deepen AI-led Digital Transformation Capabilities23.10.2025 16:30:00 EEST | Press release
Andersen Consulting strengthens its technology and business transformation capabilities through a Collaboration Agreement with Acronotics, a rapidly growing digital consulting firm headquartered in the UK with a presence in the U.S. and India. As a specialist in AI-led business transformation, Acronotics works with Fortune 500 companies to accelerate digital transformation by harnessing the power of AI. The firm has deep expertise across manufacturing, banking and financial services, retail, fast-moving consumer goods, and high-tech industries, with a strong focus on AI/ML, Generative AI, and RPA technology stacks. Acronotics delivers end-to-end services including the design, development, and implementation of Agentic AI and RPA-based process automation solutions. Leveraging its proprietary Automated Digital Worker Management platform, Radium.ai, the firm helps clients manage and monitor their digital workforce effectively. "Collaborating with Andersen Consulting enables us to scale gl
Crexendo and NUSO Partner to Deliver Global Cloud Communications Capabilities23.10.2025 16:15:00 EEST | Press release
NUSO, a leading provider of cloud communications service delivery, today announced it has been chosen by Crexendo®, Inc. (NASDAQ:CXDO), an award-winning software technology company that is a premier provider of cloud communication platform software and unified communication as a service (UCaaS) offerings, including voice, video, contact center, and managed IT services tailored to businesses of all sizes, to be a preferred carrier for the Crexendo cloud communications platform. The expanded partnership allows Crexendo platform licensees to offer cloud communications capabilities over NUSO’s global delivery network, unlocking new revenue opportunities for service providers. With NUSO’s carrier footprint in more than 40 countries, the Crexendo platform now offers global service delivery with industry-leading call quality, uptime, and emergency calling compliance. Platform providers can now offer global service delivery to over 6 million end users worldwide who rely on Crexendo’s Netsapien
SK pharmteco Boosts Domestic Peptide Scale-Up with Investment in California Facility23.10.2025 16:03:00 EEST | Press release
SK pharmteco, a global contract development and manufacturing organization (CDMO), announced today a $6.1 million investment in its Rancho Cordova facility to expand and equip a new lab and CGMP-Kilo-scale facility for Solid-Phase Peptide Synthesis (SPPS) and purification. This expansion, combined with SK pharmteco’s industry-leading chromatography expertise and existing development and manufacturing capabilities in the United States, positions the company to meet the rising demand for U.S. peptide development and domestic clinical and commercial manufacturing. "The investment in our California facility represents a key milestone in our strategic growth and demonstrates an unwavering dedication to the domestic biopharma sector,” said Joerg Ahlgrimm, CEO of SK pharmteco. “Peptides are a vital and rapidly advancing therapeutic category. This project highlights our ongoing commitment to furthering their development and manufacturing.” “We are expanding our capacity to meet the increasing
Vertex Presents New Data Across Portfolio of Cystic Fibrosis Medicines Including ALYFTREK ® at the North American Cystic Fibrosis Conference23.10.2025 16:00:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the presentation of multiple abstracts demonstrating the clinical benefits of treatment with CFTR modulators, including the Company’s most recently approved medicine, ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor), at the North American Cystic Fibrosis Conference (NACFC) held from October 22-25 in Seattle, Washington. Several of the abstracts that will be presented at this year’s conference demonstrate that improvement in CFTR function, as measured by reduction in sweat chloride (SwCl), is associated with improved outcomes in people with cystic fibrosis (CF). ALYFTREK has shown greater reductions in sweat chloride compared to TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Phase 3 trials, suggesting that ALYFTREK has the potential for even greater improvements in quality of life and other health-related outcomes. Data being presented on ALYFTREK and on correlation between lower SwCl and improved clinical
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom